Literature DB >> 23443279

Concomitant overexpression of EGFR and CXCR4 is associated with worse prognosis in a new molecular subtype of non-small cell lung cancer.

Alya A Al Zobair1, Barrak F Al Obeidy, Lei Yang, Chunxu Yang, Yang Hui, Haijun Yu, Fang Zheng, Guifang Yang, Conghua Xie, Fuxiang Zhou, Yunfeng Zhou.   

Abstract

Although the relationships between CXCR4 and EGFR expression and survival in non‑small cell lung cancer (NSCLC) have been studied independently, dual CXCR4/EGFR tumor status and its relationship with survival has not been previously investigated. In the present study, we examined the relationship between CXCR4 expression, EGFR expression and dual CXCR4/EGFR expression and survival in patients with NSCLC (n=125) using immunohistochemical techniques. Overall survival was estimated using Kaplan-Meier and Cox proportional hazards models adjusting for patient age, tumor stage and type of treatments. Patients with CXCR4-positive tumors were significantly associated with distant metastasis and tended to have poorer prognosis compared to patients with CXCR4-negative tumors (HR=2.172, 95% CI=1.229‑3.839). No significant association between EGFR expression and survival was found; however co-expression of CXCR4/EGFR was a significant prognostic factor of worse overall survival (HR=2.741, 95% CI=1.330‑5.741). Furthermore, we showed that EGF enhanced the expression of CXCR4 in NSCLC cells through the PI-3K pathway, and treatment of NSCLC cells with EGFR phosphorylation inhibitor, AG1478, resulted in downregulation of the expression of CXCR4. These results suggest an important interaction between CXCR4 and EGFR intra-cellular pathways that may activate signals of tumor progression and may provide a valid explanation for the poor overall survival rate of patients whose co-expression of CXCR4 and EGFR is detected in tissue sections. Based on EGFR and CXCR4 expression, new molecular subtypes of NSCLC established in the present study can be used for customization of NSCLC treatment. Our results also showed that EGFR and CXCR4 are potential therapeutic targets for NSCLC and that simultaneous inhibition of EGFR and CXCR4 in NSCLC patients with concomitant expression of both CXCR4 and EGFR may be an effective treatment strategy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23443279     DOI: 10.3892/or.2013.2254

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  21 in total

1.  Chemokine receptor CXCR4 expression and lung cancer prognosis: a meta-analysis.

Authors:  Jin-Xiao Liang; Wei Gao; Yong Liang; Xin-Ming Zhou
Journal:  Int J Clin Exp Med       Date:  2015-04-15

Review 2.  Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy.

Authors:  Weiqiang Zhou; Shanchun Guo; Mingli Liu; Matthew E Burow; Guangdi Wang
Journal:  Curr Med Chem       Date:  2019       Impact factor: 4.530

3.  Disruption of actin filaments and suppression of pancreatic cancer cell viability and migration following treatment with polyisoprenylated cysteinyl amides.

Authors:  Augustine T Nkembo; Olufisayo Salako; Rosemary A Poku; Felix Amissah; Elizabeth Ntantie; Hernan Flores-Rozas; Nazarius S Lamango
Journal:  Am J Cancer Res       Date:  2016-11-01       Impact factor: 6.166

4.  The clinicopathological and prognostic value of CXCR4 expression in patients with lung cancer: a meta-analysis.

Authors:  Liping Qiu; Yuanyuan Xu; Hui Xu; Biyun Yu
Journal:  BMC Cancer       Date:  2022-06-21       Impact factor: 4.638

5.  Somatostatin and CXCR4 expression patterns in adenocarcinoma and squamous cell carcinoma of the lung relative to small cell lung cancer.

Authors:  Claudia Stumpf; Daniel Kaemmerer; Elisa Neubauer; Jörg Sänger; Stefan Schulz; Amelie Lupp
Journal:  J Cancer Res Clin Oncol       Date:  2018-08-03       Impact factor: 4.553

6.  Expression of CXCR4 and non-small cell lung cancer prognosis: a meta-analysis.

Authors:  Kun Liu; Cihang Bao; Nengliang Yao; Chao Miao; John Varlotto; Qiang Sun; Xiaojie Sun
Journal:  Int J Clin Exp Med       Date:  2015-05-15

Review 7.  Chemokines and their receptors in lung cancer progression and metastasis.

Authors:  Zeng-Hui Cheng; Yu-Xin Shi; Min Yuan; Dan Xiong; Jiang-Hua Zheng; Zhi-Yong Zhang
Journal:  J Zhejiang Univ Sci B       Date:  2016-05       Impact factor: 3.066

8.  Overexpression of CXCR4 promotes invasion and migration of non-small cell lung cancer via EGFR and MMP-9.

Authors:  Jianhong Zuo; Meiling Wen; Sai Li; Xiu Lv; Lei Wang; Xiaohong Ai; Mingsheng Lei
Journal:  Oncol Lett       Date:  2017-10-11       Impact factor: 2.967

9.  Interaction between CXCR4 and EGFR and downstream PI3K/AKT pathway in lung adenocarcinoma A549 cells and transplanted tumor in nude mice.

Authors:  Juan Wu; Ying Liu; Yaling Ma; Rui Wang; Xiaokun Ji; Yan Zhang; Yun Du
Journal:  Int J Clin Exp Pathol       Date:  2020-02-01

Review 10.  CXCR4 over-expression and survival in cancer: a system review and meta-analysis.

Authors:  Hongli Zhao; Liyuan Guo; Hong Zhao; Jiaxin Zhao; Hao Weng; Bin Zhao
Journal:  Oncotarget       Date:  2015-03-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.